Table 1 Demographic characteristics, comorbidities, and medications of patients with DM taking or not taking SGLT2i
|  | Non-SGLT2i group (n = 7,988) | SGLT2i group (n = 7,988) | P |
|---|---|---|---|
n (%) / Mean ± SD | n (%) / Mean ± SD | ||
Male sex | 4,458 (55.81) | 4,445 (55.65) | 0.836 |
Age, years | Â | Â | 0.861 |
 20–39 | 532 (6.66) | 549 (6.87) |  |
 40–59 | 3,780 (47.32) | 3,778 (47.30) |  |
 ≥ 60 | 3,676 (46.02) | 3,661 (45.83) |  |
 Mean | 57.81 ± 11.75 | 57.66 ± 11.79 | 0.418 |
Comorbidities | Â | Â | Â |
 HT | 6,184 (77.42) | 6,167 (77.20) | 0.748 |
 HL | 6,972 (87.28) | 6,979 (87.37) | 0.868 |
 Asthma | 1,371 (17.16) | 1,384 (17.33) | 0.785 |
 COPD | 1,557 (19.49) | 1,559 (19.52) | 0.968 |
 ARD | 289 (3.62) | 296 (3.71) | 0.768 |
Follow-up period, years | 0.91 ± 0.58 | 0.94 ± 0.41 | < 0.001 |